Search for cancer prevention, treatment and quality of life studies enrolling people with or at high risk for hereditary cancers.
Sign up for hereditary cancer research updates.
Featured Studies Results
Study Type: Treatment
Pfizer Clinical Trials for Metastatic Prostate Cancer are Now Enrolling
Treatment
Men aged 18 years or older with metastatic prostate cancer
Vaccines for Pancreatic Cancer After Chemotherapy
Clinicaltrials.gov identifier:
NCT05111353
Treatment
Treatment study for people with pancreatic cancer
Effectiveness of Lymph Node Mapping to Reduce the Risk of Swelling in the Legs in Patients with Stage I Endometrial Cancer
Clinicaltrials.gov identifier:
NCT05646316
Treatment
People with stage I endometrial cancer who are having a hysterectomy
New Treatment in People with Triple Negative Breast Cancer or Advanced Solid Tumors
Clinicaltrials.gov identifier:
NCT06022029
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas
The Phoenix Trial: Cemiplimab for Patients with Localized dMMR Colon Cancer
Clinicaltrials.gov identifier:
NCT05961709
Treatment
This study will examine how well Cemiplimab works for patients with localized colon cancer who have dMMR
Using ctDNA for Earlier Detection and Treatment of Recurrence or Spread after Treatment for Stage 3 Colon Cancer
Clinicaltrials.gov identifier:
NCT03803553
Treatment
Monitoring and treatment study for people who completed treatment for stage 3 colon cancer
Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting
Clinicaltrials.gov identifier:
NCT05253651
Treatment
People with HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting
Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)
Treatment
Hispanic and Latino people diagnosed with colorectal cancer
Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-L1 Inhibitor
Clinicaltrials.gov identifier:
NCT03607890
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
Chemotherapy, Bevacizumab, and/or Atezolizumab for dMMR / MSI-H Metastatic Colorectal Cancer (COMMIT Study)
Clinicaltrials.gov identifier:
NCT02997228
Treatment
This is a treatment study is for people with metastatic colorectal cancer
Nivolumab, Nivolumab Plus Ipilimumab, or Chemotherapy for Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (CheckMate 8HW)
Clinicaltrials.gov identifier:
NCT04008030
Treatment
People with metastatic colorectal cancer that is MSI-High
If you would like a more in-depth search, visit our In-Depth Search Tool that searches for studies in FORCE’s database and in clinicaltrials.gov
Sponsored By:
